Vertex Pharmaceuticals Incorporated (VRTX)
by | Posted 4.10.2012 | Post Comment (No Comments)

About Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Incorporated (VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases. The Company’s two products are INCIVEK (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus (HCV), infection, and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis (CF), who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), gene.

For more info: Vertex Pharmaceuticals Website, Vertex Pharmaceuticals Investor Relations

Recent Dividend Posts About Vertex Pharmaceuticals Incorporated (VRTX)

Vertex Pharmaceuticals Could See Strong Gains From Incivek@ Dividend Kings
-more coming soon

Vertex Pharmaceuticals Incorporated (VRTX)

[stocks s=”VRTX”]